| Trial ID: | L4924 |
| Source ID: | NCT05078255
|
| Associated Drug: |
Semaglutide 1.34 Mg/Ml [Ozempic]
|
| Title: |
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Obesity
|
| Interventions: |
DRUG: Semaglutide 1.34 MG/ML [Ozempic]|DRUG: Glucose-dependent insulinotropic polypeptide (GIP)|OTHER: Semaglutide 1.34 mg/ml placebo|OTHER: GIP placebo
|
| Outcome Measures: |
Primary: Mean glucose levels (assessed by blinded continuous glucose monitoring (CGM)), The primary outcome is change in 14-day mean glucose levels (assessed by CGM) during the last 14 days of the intervention period as compared to 14-day mean glucose levels during the last 14 days of the run-in period., 14-day mean glucose levels during the last 14 days of the intervention period as compared to 14-day mean glucose levels during the last 14 days of the run-in period. |
|
| Sponsor/Collaborators: |
Sponsor: Asger Lund, MD
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
61
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-01-27
|
| Completion Date: |
2025-01-24
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-14
|
| Locations: |
Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Capital Region, DK-2900, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT05078255
|
